Rationale Surrounding Luspatercept as Potential First-Line Treatment Option for Patients With MDS

Opinion
Video

Dr Jamie L. Koprivnikar discusses the rationale surrounding luspatercept as a potential first-line treatment option for patients with myelodysplastic syndrome, and if it would have been an appropriate therapy for the patient in the presented case study.

Newsletter

Stay up to date on practice-changing data in community practice.

Recent Videos
1 expert in this video
1 expert in this video
1 expert in this video
Related Content